Introduction
============

Liver cancer is the fifth most common type of cancer and the third leading cause of cancer-associated mortality in the worldwide population ([@b1-etm-0-0-3283]). The incidence and mortality rates of liver cancer are continuously increasing, with \~700,000 people diagnosed with liver cancer annually, among which hepatocellular carcinoma (HCC) constitutes \>80% of cases ([@b2-etm-0-0-3283],[@b3-etm-0-0-3283]). The hepatitis B virus (HBV) is a major risk factor for liver cancer ([@b4-etm-0-0-3283]). HBV is an oncogenic virus that can cause HCC through direct and indirect signaling pathways ([@b5-etm-0-0-3283]). Continuous hepatocyte injury and regeneration in liver disease result in increased liver cell turnover and accumulation of critical mutations in the host genome, which can in turn cause gene alterations, including the activation of oncogenes or inactivation of tumour suppressor genes ([@b5-etm-0-0-3283]). Since early diagnosis of liver cancer is challenging, the majority of HCC patients suffer from poor prognosis. Although great progress has been achieved in cancer treatment using methods such as surgery, liver transplantation, radiofrequency ablation and transcatheter arterial chemoembolization, the majority of HCC patients succumb due to invasion or distant metastasis to other organs ([@b6-etm-0-0-3283],[@b7-etm-0-0-3283]). Therefore, research has focused on examining the molecular mechanisms underlying invasion and metastasis, as well as investigating the significant molecular markers of HCC metastasis and identifying novel targets. One of the most effective strategies for the successful management of HCC is the prevention of metastasis of cancer cells in order to reduce the mortality rate and improve the prognosis of liver cancer ([@b8-etm-0-0-3283]).

The underlying mechanism of cancer invasion and metastasis is a complicated multistep process involving multiple genetic and molecular alterations ([@b9-etm-0-0-3283]). Chromosome region maintenance 1 (CRM1), also known as exportin 1, was initially identified in eukaryotic cells, while human CRM1 was first attained by cloning in 1997 by Kudo *et al* ([@b10-etm-0-0-3283]). It consists of 1,071 amino acids, which can maintain the structure and function of chromosomes in the process of mitosis ([@b10-etm-0-0-3283]). CRM1 is a major nuclear export protein in mammals, which facilitates the transport of RNAs, proteins or other macromolecules across the nuclear membrane to the cytoplasm ([@b11-etm-0-0-3283]--[@b14-etm-0-0-3283]). In addition, CRM1 recognizes the leucine-rich nuclear export signal (NES) sequence. Numerous cargo proteins that are rich in NES sequences, including tumor suppressor protein p53, p27, p21 and Forkhead box O, depend on CRM1 for nuclear export function ([@b15-etm-0-0-3283]--[@b19-etm-0-0-3283]).

The transportation of macromolecules across the nuclear membrane is critical for the proper functioning of living cells. Accumulating evidence has suggested that cancer cells are able to escape antineoplastic mechanisms and benefit from prosurvival signals through the dysregulation of this system ([@b20-etm-0-0-3283]). The protein CRM1 is the only member of the karyopherin-β protein family that contributes to the nucleocytoplasmic trafficking, and is considered to be an anti-apoptotic oncogenic protein in transformed cells ([@b21-etm-0-0-3283]). In cancer cells, overexpression of CRM1 results in alterations in nucleocytoplasmic trafficking and deregulation of ribosomal biogenesis, as well as in aberrant cytoplasmic localization of tumor suppressor proteins, cell cycle regulators and pro-apoptotic proteins ([@b20-etm-0-0-3283]). A large number of studies ([@b22-etm-0-0-3283]--[@b24-etm-0-0-3283]) have shown that imbalance of cell proliferation and cell death due to disorder of the cell cycle is the major cause of malignancy. Therefore, abnormally high expression of CRM1 is correlated with poor patient prognosis in various malignancies. For instance, Giovanni *et al* ([@b25-etm-0-0-3283]) have reported that overexpression of CRM1 is associated with survival difference of various tumors, including pancreatic, lung, ovarian and cervical cancer, as well as in osteosarcoma and leukemia. Anguinomycin and goniothalamin were found to be inhibitors of CRM1 ([@b26-etm-0-0-3283],[@b27-etm-0-0-3283]), thus the development of CRM1-specific small molecules as novel anti-cancer agents is considered. Currently, therapeutic targeting of CRM1 has emerged as the original specific inhibitor of CRM1, followed by the development of several next-generation small molecules, such as KPT-330 which is a selective inhibitor of nuclear export ([@b20-etm-0-0-3283],[@b28-etm-0-0-3283]--[@b29-etm-0-0-3283]).

Since the role of CRM1 in oncogenesis has been revealed by various studies and the anti-tumor mechanism of CRM1 inhibition is gradually elucidated ([@b30-etm-0-0-3283]--[@b33-etm-0-0-3283]), it is crucial to focus on the association of CRM1 expression with malignancy and clinical features. Therefore, the present study aimed to detect the CRM1 protein expression in primary liver carcinoma and adjacent cancer tissues in order to investigate its association with clinical and pathological features using an immunohistochemical assay. Furthermore, the study aimed to provide new experimental evidence for the molecular mechanism of tumor growth, invasion, metastasis and molecular therapy of primary liver carcinoma.

Materials and methods
=====================

### Human tissue samples

A total of 152 tumor tissues and adjacent normal tissues (which were located \<2 cm from the cancer tissue and were used as the controls) were obtained between January 2009 and June 2014. The liver samples were provided by the First Affiliated Hospital of Dalian Medical University (Dalian, China). All liver samples were collected during surgery and preserved in 10% formaldehyde solution at room temperature. Approximately 1×1×0.3 cm^3^ liver samples were obtained and fixed with 10% formalin for 24 h. The tissue samples were subsequently dehydrated using a fully-automated tissue processor (Tissue-Tek^®^ VIP^®^ 6) and embedded in paraffin using a paraffin-embedding device (Leica EG1160). All enrolled patients were diagnosed with primary cancer of the liver by pathological examination, which was based on the World Health Organization classification of tumors of the digestive system ([@b34-etm-0-0-3283]). Communication was conducted with patients prior to surgery and all patients voluntarily participate in the present study, providing written informed consents. Information collected from the patient records included the gender, age, cirrhosis status, hepatitis B surface antigen (HBsAg), hepatitis B envelope antigen (HBeAg), α-fetoprotein (AFP), carcinoembryonic antigen (CEA), differentiation degree (including high, middle or low differentiation) ([@b35-etm-0-0-3283]) and American Joint Committee on Cancer (AJCC) stage ([@b36-etm-0-0-3283]). HBsAg, HBeAg, CEA and AFP levels were measured using an ELISA kits (Roche Cobas e601 Analyzer; Roche Diagnostics GmbH, Mannheim, Germany). Detailed clinical and pathological features of these patients are shown in [Table I](#tI-etm-0-0-3283){ref-type="table"}.

The expression levels of CRM1 in the tumor and adjacent normal control tissues were then examined. Furthermore, the clinical and pathological features of 152 liver cancer patients and their association with CRM1 were also investigated. The present study was approved by the Ethics Committee of the The First Affiliated Hospital of Dalian Medical University.

### Instruments and reagents

A Leica EG1160 paraffin-embedding device, a Leica RM2245 microtome, a drying device and a Leica DM2500 microscope were purchased from Leica Biosystems (Wetzlar, Germany). In addition, a Tissue-Tek VIP6 fully-automated tissue processor was purchased from Sakura Finetek (Tokyo, Japan). The primary antibody used in the present study was a rabbit anti-human CRM1 antibody (dilution, 1:100; ab191081; Abcam, Cambridge UK), and the secondary antibody was a horseradish peroxidase-conjugated goat anti-mouse/rabbit immunoglobulin G polymer (dilution, 1:1,000; Fuzhou Maixin Biological Technology Development Company, Fujian, China). Furthermore, phosphate-buffered saline (PBS), 3,3′-diaminobenzidine (DAB) chromogenic reagent and Tris-EDTA buffer (pH 9.0) were purchased from Zhongshan Jinqiao Biotechnology Co., Ltd. (Beijing, China). Other reagents, including xylene and ethanol (70, 90 and 100%), were purchased from Shunda Chemicals Co. Ltd. (Xi\'an, China).

### Immunohistochemical analysis

The expression and intracellular localization of CRM1 in tumor and adjacent normal tissues were determined immunohistochemically. The tissue samples were dehydrated using the fully automated tissue processor (Tissue-Tek VIP6) and embedded in paraffin using a paraffin-embedding device (Leica EG1160). The tissue samples were then sectioned in 2-µm specimens with a microtome (Leica RM2245) and dried at 60°C for 2 h using a drying device. Subsequent to deparaffinization in xylene for 10 min and rehydration in ascending grades of ethanol (70% for 2 min, 95% for 2 min and 100% for 2 min), high temperature antigen retrieval was conducted for 3 min using 0.01 M Tris-EDTA buffer (pH 9.0) and a standard pressure-cooker. All sections were subjected to endogenous biotin blocking (3% H~2~O~2~)and incubated for 10 min at room temperature. Tissues were washed with PBS and then incubated with the CRM1 primary antibody (ab191081) at 4°C overnight. Subsequently, the tissues were washed with PBS and incubated with secondary antibody for 1 h at room temperature. After tissues were washed with PBS, a DAB chromagen substrate was used, and the tissues were washed in PBS and stained with hematoxylin (Shunda Chemical Co., Ltd., Xi\'an, China). Following dehydration in ascending grades of alcohol, clearing in xylene, drying and sealing with resinene tablets (Ziyi Co., Shanghai, China), the tissue sections were examined under a Leica DM2500 microscope.

Two experienced pathologist independently observed the distribution characteristics of CRM1 expression using an optical microscope. Brown staining indicated positive staining for CRM1. Five high-power fields (magnification, ×200) of each section were randomly selected and images were captured with the Leica DM2500 microscope. Next, the area of interest was selected and the value of optical density of each photo was detected by an image analysis software (Image-Pro Plus version 6.0; Media Cybernetics, Inc., Rockville, MD, USA). The mean value of the immunohistochemical optical density was determined as the final expression value of each tissue sample.

### Statistical analysis

All statistical analyses were performed using SPSS version 19.0 (IBM Corp., Armonk, NY, USA). The results are expressed as the mean ± standard deviation. Comparisons between the mean values were performed using Student\'s t test, analysis of variance and Fisher\'s least significant difference test. A P-value of \<0.05 was considered as statistically significant.

Results
=======

### Immunohistochemical analysis results

Since all patients did not exhibit CRM1 expression in the adjacent normal tissue samples, only 101 cases with CRM1 expression in both the tumor tissue and adjacent normal tissue samples were further analyzed. The results indicated that CRM1 was highly expressed in both tumor and adjacent normal tissues, but the expression was not statistically significant between the two groups (P=0.106; [Table II](#tII-etm-0-0-3283){ref-type="table"}). Subsequently, the association between CRM1 expression and individual clinical features of the patients was further investigated. CRM1 expression of adjacent normal tissues was found to be significantly higher compared with that of the tumor tissues in the low differentiation (P=0.004; [Fig. 1](#f1-etm-0-0-3283){ref-type="fig"}) and negative HBeAg (P=0.035; [Fig. 2](#f2-etm-0-0-3283){ref-type="fig"}) specimens. However, as shown in [Table II](#tII-etm-0-0-3283){ref-type="table"}, the CRM1 expression of tumor tissues was not significantly lower compared with that in the adjacent normal tissues for other parameters (all P\>0.05), including gender (male, P=0.144; female, P=0.508), age (patients ≤55 years, P=0.614; patients \>55 years, P=0.069), cirrhosis status (positive, P=0.434; negative, P=0.080), positive HBsAg (P=0.091), negative HBsAg (P=0.691), positive HBeAg (P=0.474), AFP (≤400 µg/l, P=0.255; \>400 µg/l, P=0.133), CEA (≤5 µg/l, P=0.174; \>5 µg/l, P=0.843), tumor diameter (≤5 cm, P=0.097; \>5 cm, P=0.680) and AJCC stage I (P=0.084; [Fig. 3](#f3-etm-0-0-3283){ref-type="fig"}). Since patients with AJCC stage II, III or IV were few in numbers, further analysis was not performed.

### Analysis of CRM1 expression in tumor tissues

As shown in [Fig. 4](#f4-etm-0-0-3283){ref-type="fig"}, positive CRM1 expression was found to be significantly correlated with low differentiation (P=0.045). However, negative associations were detected between positive CRM1 expression and other parameters, including gender (P=0.566), age (P=0.570), cirrhosis (P=0.457), HBsAg (P=0.412), HBeAg (P=0.322), AFP (P=0.308), CEA (P=0.225), tumor diameter (P=0.428) and AJCC stage (all P\>0.05; [Table III](#tIII-etm-0-0-3283){ref-type="table"}).

### Analysis of CRM1 expression in adjacent normal tissue

As shown in [Fig. 5](#f5-etm-0-0-3283){ref-type="fig"}, positive CRM1 expression was found to be significantly correlated with the tumor diameter in adjacent normal tissues (P=0.004). However, negative associations were detected between positive CRM1 expression and other parameters, including gender (P=0.383), age (P=0.144), cirrhosis (P=0.394), HBsAg (P=0.257), HBeAg (P=0.125), AFP (P=0.718), CEA (P=0.355), differentiation degree and AJCC stage (all P\>0.05; [Table IV](#tIV-etm-0-0-3283){ref-type="table"}).

Discussion
==========

Epidemiological investigations have shown that primary liver cancer is connected with polygenic susceptibility ([@b37-etm-0-0-3283]). The development of cancer is a complicated process that includes cell proliferation, inactivation of tumor-suppressor gene and activation of oncogene mediated by numerous signaling cascades ([@b9-etm-0-0-3283],[@b37-etm-0-0-3283]). CRM1, a member of the karyopherin-β protein family, is a nuclear export receptor that, upon binding with RanGTP, is able to recognize the substrates rich in NES ([@b21-etm-0-0-3283],[@b38-etm-0-0-3283]). The CRM1 signaling cascade is important in mediating the expression of growth factors and cytokines, serving a critical role in the malignant transformation of cells ([@b30-etm-0-0-3283]--[@b33-etm-0-0-3283],[@b38-etm-0-0-3283]--[@b41-etm-0-0-3283]). To date, studies have demonstrated that CRM1 is strongly expressed in various types of tumor cells, and it may promote malignant transformation of mammal cells. In addition, its overexpression is associated with cell carcinogenesis and poor prognosis of solid tumor ([@b42-etm-0-0-3283]--[@b45-etm-0-0-3283]). In human glioma cells overexpressing CRM1, tumor cell growth was promoted by the nuclear export of p27 protein ([@b42-etm-0-0-3283]). In lung cancer, CRM1 was found to increase tumor growth by changing the suppressor gene p53 subcellular localization ([@b43-etm-0-0-3283]).

In the present study, due to limited availability of normal human liver tissues, tumor tissues were collected and their adjacent normal tissues were used as the control group. The current study detected the CRM1 expression in tumor tissues and adjacent normal tissues, and estimated the association of CRM1 expression with various clinical and pathological features, including the patient gender, age, cirrhosis statis, HBsAg, HBeAg, tumor diameter, AFP, differentiation degree and AJCC stage. The results aimed to provide further evidence on whether CRM1 serves an important role in liver cancer invasion and metastasis, and whether it is an important molecular mechanism underlying the progression of liver cancer.

The results of the present study demonstrated that although male patients \>55 years of age had higher expression levels of CRM1 in adjacent normal tissues compared with tumor tissues, no significant difference was observed. The number of male patients with liver cancer were higher than female patients, and El-Serag *et al* ([@b2-etm-0-0-3283]) also reported that the ratio of affected men to affected women was between 2:1 and 4:1. Men are therefore more likely to develop liver cancer than women, but whether liver cancer metastasis affects a gender or age more than the other requires further study. The results of the present study revealed that CRM1 was expressed similarly in tumor and adjacent normal tissues. However, a higher CRM1 expression in adjacent normal tissues compared with that in tumor tissues was found to be significantly correlated with the differentiation degree. In addition, in the tumor tissue group, positive CRM1 expression was significantly correlated with the differentiation degree, whereas in the adjacent normal tissue group, positive CRM1 expression was observed to be significantly correlated with the tumor diameter. A low degree of differentiation and higher tumor diameter resulted in increased CRM1 expression in adjacent normal tissues; thus, CRM1 may participate in tumor cell metastasis and invasion to adjacent normal tissues. Numerous studies have confirmed an increased expression of CRM1 in various solid tumors (such as glioblastoma, pancreatic cancer, ovarian cancer and cervical cancer) and hematologic malignancies ([@b33-etm-0-0-3283],[@b44-etm-0-0-3283]). Furthermore, previous studies revealed that the nuclear export of 221 types of NES-containing proteins was mediated by CRM1. Moreover, numerous NES-containing proteins are critical signaling molecules of tumor cell proliferation and malignant transformation ([@b21-etm-0-0-3283]--[@b52-etm-0-0-3283]). It is also estimated that CRM1 inhibitors may effectively inhibit the proliferation of tumor cells and accelerate apoptosis, while their efficacy may be enhanced when combined with chemotherapy drugs ([@b21-etm-0-0-3283]).

In fact, HBV is a major cause of primary cancer of liver ([@b4-etm-0-0-3283]). A study by Forgues *et al* ([@b52-etm-0-0-3283]) has investigated the interaction of the HBV X protein with the CRM1-dependent nuclear export pathway and suggested that CRM1 may serve a role in HBV X protein-mediated liver carcinogenesis. The oncogenic HBV X protein contains a functional NES motif and mutations of this motif result in nuclear redistribution of HBV X protein. In the present study, the association between HBsAg/HBeAg and CRM1 expression in tumor tissues and adjacent normal tissues was investigated. The results showed that the CRM1 expression in adjacent normal tissues with positive HBsAg was higher compared with that in the tumor tissue group, but with no statistically significant difference observed. However, CRM1 expression in adjacent normal tissues was significantly higher compared with that in tumor tissues with a negative HBeAg status. According to these findings, it is suggested that liver cancer in patients with HBV infection, particularly patients with negative HBeAg, is more likely to present invasion and metastasis. E antigen is encoded by the pre-C gene, and a longer duration of hepatitis B accompanied by a mutation to the pre-C gene will result in the absence of E antigen in the serum. However, the HBV DNA load will remain high, so HBeAg-negative patients may experience more severe liver inflammation and are more likely to develop liver cirrhosis and liver cancer as compared with HBeAg-positive patients ([@b53-etm-0-0-3283]).

HBV-associated or hepatitis C virus-associated liver fibrosis and cirrhosis are considered to be risk factors for the development of primary liver cancer ([@b54-etm-0-0-3283],[@b55-etm-0-0-3283]). The majority of primary liver cancer cases (even up 80% of cases) occurred in patients with HBV infection or cirrhosis in China ([@b56-etm-0-0-3283]). Cirrhosis has a significantly effect on the liver microenvironment, including increased extracellular matrix proteins and cytokines, angiogenesis and changes in the immune regulation mechanism. Changes in the liver microenvironment also affect the environment of tumor cells. In the present study, a negative association was detected between positive CRM1 expression and cirrhosis in the tumor tissues and adjacent normal tissues; however, CRM1 expression in patients with cirrhosis was higher compared with that in non-cirrhotic patients in both tissue groups. This increased trend may suggest that cirrhosis is a dependent risk factor of invasion and metastasis of liver cancer. The study by Pascale *et al* ([@b57-etm-0-0-3283]) revealed that the CRM1 expression in liver fibrosis, cirrhosis and liver cancer increased by 2--2.9 times when compared with the expression in normal livers of mice ([@b57-etm-0-0-3283]). Therefore, overexpression of CRM1 may be an important molecular mechanism of cirrhosis evolution in liver cancer.

AFP and CEA are important serum markers of cancer diagnosis, and are usually applied in combination ([@b58-etm-0-0-3283]). In the present study, patients with high serum levels of AFP and CEA exhibited higher CRM1 expression both in tumor tissues and adjacent normal tissues compared with those with low levels of AFP and CEA. However, significant differences were not observed. These results suggested that high levels of AFP and CEA may be associated with the degree of malignancy of the liver cancer and how prone it is to metastasis. Ma *et al* ([@b58-etm-0-0-3283]) also reported that AFP levels were predictive of the malignant features and prognosis of liver cancer. However, the current study presented certain limitations. Although the sample size of the study is not particularly small, due to limited availability of fresh liver samples, only immunohistochemical assay was used to assess the CRM1 expression. Studies with much larger sample sizes and novel experimental methods are required to further investigate the molecular mechanism of tumor invasion and metastasis.

In conclusion, CRM1 is suggested to serve an important role in the invasion and metastasis of primary liver cancer. CRM1 expression was found to be associated with the differentiation degree and diameter of the tumor. A lower differentiation degree and larger tumor diameter resulted in higher CRM1 expression in adjacent normal tissues and increased the possibility of invasion and metastasis. Furthermore, chronic hepatitis B patients with negative HBeAg were at a high risk of invasion and metastasis. Therefore, a high expression of CRM1 may be an important molecular mechanism of cirrhosis evolution in liver cancer.
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![Immunohistochemical analysis of CRM1 expression in (A) adjacent normal control and (B) tumor tissues, in the low differentiation group. (C) CRM1 expression was higher in the adjacent normal tissues compared with the tumor tissues (low differentiation group). CRM1, chromosome region maintenance 1; IOD, immunohistochemical optical density. \*P\<0.05, vs. tumor tissues.](etm-12-01-0059-g00){#f1-etm-0-0-3283}

![Immunohistochemical analysis of CRM1 expression in (A) adjacent normal control and (B) tumor tissues, in the negative HBeAg group. (C) CRM1 expression in adjacent normal tissues is higher compared with that in tumor tissues, in the negative HBeAg specimens. CRM1, chromosome region maintenance 1; HBeAg, hepatitis B envelope antigen; IOD, immunohistochemical optical density. \*P\<0.05, vs. tumor tissues.](etm-12-01-0059-g01){#f2-etm-0-0-3283}

![Immunohistochemical analysis of CRM1 expression in (A) adjacent normal control and (B) tumor tissues, including the following groups from the first column of the first row to the fourth column of the third row: Male, female, age \>55 years, age ≤55 years, cirrhosis, absence of cirrhosis, positive HBsAg, negative HBsAg, positive HBeAg, AFP \>400 µg/l, AFP ≤400 µg/l, CEA \>5 µg/l, CEA ≤5 µg/l, tumor diameter \>5 cm, tumor diameter ≤5 cm and AJCC stage I. CRM1, chromosome region maintenance 1; HBeAg, hepatitis B envelope antigen; AFP, α-fetoprotein; CEA, carcinoembryonic antigen.](etm-12-01-0059-g02){#f3-etm-0-0-3283}

![Association between CRM1 expression of tumor tissues and differentiation degree. CRM1, chromosome region maintenance 1; IOD, immunohistochemical optical density. \*P\<0.05, vs. moderate.](etm-12-01-0059-g03){#f4-etm-0-0-3283}

![Association between CRM1 expression of adjacent normal tissues and diameter. CRM1, chromosome region maintenance 1; IOD, immunohistochemical optical density. \*P\<0.05, vs. ≤5 cm.](etm-12-01-0059-g04){#f5-etm-0-0-3283}

###### 

Clinical and pathological features of patients with primary cancer of the liver.

  Variable                 Percentage (%)
  ------------------------ --------------------------
  No. of patients          152 (100.0)
  Gender                   
    Male                   122 (80.3)
    Female                 30 (19.7)
  Age, years               
    ≤55                    77 (50.7)
    \>55                   75 (49.3)
  Diameter, cm             
    ≤5                     86 (56.6)
    \>5                    66 (43.4)
  No. of tumors            
    1                      136 (89.5)
    ≥2                     16 (10.5)
  Cirrhosis                
    +                      102 (67.1)
    −                      50 (32.9)
  HBsAg                    
    +                      139 (91.4)
    −                      13 (8.6)
  HBeAg                    
    +                      31 (20.4)
    −                      121 (79.6)
  AFP, µg/l                
    ≤400                   120 (79.0)
    \>400                  32 ([@b21-etm-0-0-3283])
  CEA, µg/l                
    ≤5                     116 (76.3)
    \>5                    36 (23.7)
  Differentiation degree   
    High                   32 (21.0)
    Middle                 53 (34.9)
    Low                    67 (44.1)
  AJCC stage               
    I                      131 (86.2)
    II                     9 (5.9)
    III                    10 (6.6)
    IV                     2 (1.3)

CRM1, chromosome region maintenance 1; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; AFP, α-fetoprotein; CEA, carcinoembryonic antigen; AJCC, American Joint Committee on Cancer; +, positive; -, negative.

###### 

Association of CRM1 expression of tumor and adjacent normal tissues with clinical pathological features of patients.

                           CRM1 (IOD)                                               
  ----------------- ------ ----------------------- ----------------------- -------- -------
  All patients      101    134,737.84±144,343.88   165,603.86±141,841.21   1.632    0.106
  Gender                                                                            
    Male            83     142,175.00±199,338.96   172,651.86±137,014.50   1.477    0.144
    Female            18   100,444.32±116,058.22   133,104.73±162,584.74   0.676    0.508
  Age, years                                                                        
    ≤55             54     141,103.59±165,342.28   154,336.02±128,576.80   0.507    0.614
    \>55            47     127,424.01±117,018.72   178,549.88±156,105.03   1.861    0.069
  Cirrhosis                                                                         
    +               65     149,593.95±128,705.42   169,193.31±140,717.66   −0.787   0.434
    −               36     107,914.32±167,596.64   159,122.90±145,626.71   −1.806   0.080
  HBsAg                                                                             
    +               94     132,439.61±146,800.11   166,820.07±144,761.11   −1.710   0.091
    −                 7    165,599.83±109,678.66   149,271.89±100,829.23   0.418    0.691
  HBeAg                                                                             
    +               82     138,606.82±155,005.00   153,497.11±131,531.72   −0.719   0.474
    −               19     118,040.13±85,257.80    217,854.03±174,268.98   −2.285   0.035
  AFP, µg/l                                                                         
    ≤400            86     136,995.87±149,979.55   160,477.47±140,133.43   −1.146   0.255
    \>400           15     121,691.05±113,876.58   204,903.30±153,643.40   −1.603   0.133
  CEA, µg/l                                                                         
    ≤5              81     130,923.14±148,572.40   153,332.91±136,638.43   1.732    0.174
    \>5             20     192,052.42±145,804.10   201,119.63±175,908.90   −0.214   0.843
  Diameter, cm                                                                      
    ≤5              65     131,421.49±153,865.43   172,529.67±154,822.13   −1.683   0.097
    \>5             36     140,725.71±127,204.82   153,098.93±115,767.30   −0.416   0.680
  Differentiation                                                                   
    Low             44     168,498.02±137,486.15   952,982.20±103,493.34   3.017    0.004
    Middle          35     153,890.49±139,782.16   164,034.91±135,824.15   −0.294   0.770
    High            22     172,440.15±201,919.78   178,450.43±158,258.18   0.141    0.889
  AJCC stage                                                                        
    I               91     133,074.18±141,755.58   167,146.51±144,340.17   −1.750   0.084

CRM1, chromosome region maintenance 1; IOD, immunohistochemical optical density; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer; +, positive; -, negative.

###### 

Association between CRM1 expression of tumor tissues and clinical pathological features.

  Feature           No.    CRM1 expression (IOD) in tumor tissues   T-value   P-value
  ----------------- ------ ---------------------------------------- --------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gender                                                                      
    Male            120    143,353.57±151,369.26                    0.114     0.566
    Female            30   139,825.88±156,349.77                              
  Age, years                                                                  
    ≤55               77   129,275.10±150,039.60                    −1.102    0.570
    \>55              75   156,396.40±153,464.20                              
  Cirrhosis                                                                   
    +               102    157,349.60±147,664.49                    1.715     0.457
    −                 50   112,685.13±157,300.15                              
  HBsAg                                                                       
    +               139    141,232.62±155,627.62                    −0.377    0.412
    −                 13   157,890.67±106,454.30                              
  HBeAg                                                                       
    +               120    142,652.84±157,021.42                    0.021     0.322
    −                 31   143,295.45±135,059.08                              
  AFP, µg/l                                                                   
    ≤400            120    135,903.39±147,779.25                    −0.996    0.308
    \>400             30   166,934.08±171,099.53                              
  CEA, µg/l                                                                   
    ≤5              116    135,737.99±150,342.95                    −1.244    0.225
    \>5             36     183,316.95±158,906.97                              
  Diameter, cm                                                                
    ≤5                86   140,864.01±164,325.30                    −0.166    0.428
    \>5               66   144,994.05±135,065.09                              
  Differentiation                                                             0.045^[a](#tfn4-etm-0-0-3283){ref-type="table-fn"}^, 0.155^[b](#tfn5-etm-0-0-3283){ref-type="table-fn"}^, 0.771^[c](#tfn6-etm-0-0-3283){ref-type="table-fn"}^
    Low               67   169,434.42±154,982.45                              
    Moderate          53   113,388.64±132,470.57                              
    High              32   159,589.03±136,877.62                              
  AJCC                                                                        0.997^[d](#tfn7-etm-0-0-3283){ref-type="table-fn"}^, 0.649^[e](#tfn8-etm-0-0-3283){ref-type="table-fn"}^, 0.805^[f](#tfn9-etm-0-0-3283){ref-type="table-fn"}^,
  stage                                                                       0.747^[g](#tfn10-etm-0-0-3283){ref-type="table-fn"}^, 0.821^[h](#tfn11-etm-0-0-3283){ref-type="table-fn"}^, 0.674^[i](#tfn12-etm-0-0-3283){ref-type="table-fn"}^
    I               131    141,491.21±147,973.91                              
    II                9    141,687.09±166,898.77                              
    III               10   164,408.01±208,434.76                              
    IV                2    114,490.13±121,496.74                              

Differentiation P-values:

Low vs. moderate

low vs. high

moderate vs. high. AJCC stage P-values:

I vs. II

I vs. III

I vs. IV

II vs. III

II vs. IV

III vs. IV. CRM1, chromosome region maintenance 1; IOD, immunohistochemical optical density; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer; +, positive; -, negative.

###### 

Association between CRM1 expression of adjacent normal tissues and clinical pathological features.

  Feature           Patients   CRM1 (IOD)              T-value   P-value
  ----------------- ---------- ----------------------- --------- ------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Gender                                                         
    Male            83         172,651.86±137,014.50   1.073     0.383
    Female          18         133,104.73±162,584.74             
  Age, years                                                     
    ≤55             54         154,336.02±128,576.80   −0.855    0.144
    \>55            47         178,549.88±156,105.03             
  Cirrhosis                                                      
    +               65         169,193.31±140,717.66   0.340     0.394
    −               36         159,122.89±145,626.71             
  HBsAg                                                          
    +               94         166,820.07±144,761.11   0.314     0.257
    −                 7        149,271.89±100,829.23             
  HBeAg                                                          
    +               19         217,854.03±174,268.98   1.802     0.125
    −               82         153,497.11±131,531.72             
  AFP, µg/l                                                      
    ≤400            86         160,477.47±140,133.43   −1.086    0.718
    \>400           14         204,903.30±153,643.40             
  CEA, µg/l                                                      
    ≤5              81         153,332.91±136,638.43   −0.947    0.355
    \>5             20         192,052.42±145,804.10             
  Diameter, cm                                                   
    ≤5              65         153,098.93±115,767.30   0.658     0.004
    \>5             36         172,529.66±154,822.13             
  Differentiation                                                0.653^[a](#tfn14-etm-0-0-3283){ref-type="table-fn"}^, 0.790^[b](#tfn15-etm-0-0-3283){ref-type="table-fn"}^, 0.529^[c](#tfn16-etm-0-0-3283){ref-type="table-fn"}^
    Low             44         168,498.02±137,486.15             
    Moderate        35         153,890.49±139,782.16             
    High            22         178,450.43±158,258.18             
  AJCC stage                                                     0.850^[d](#tfn17-etm-0-0-3283){ref-type="table-fn"}^, 0.690^[e](#tfn18-etm-0-0-3283){ref-type="table-fn"}^, 0.665^[f](#tfn19-etm-0-0-3283){ref-type="table-fn"}^
    I               91         167,146.51±144,340.17             
    II                5        179,673.43±153,475.79             
    III               4        137,812.58±97,291.86              

Differentiation P-values:

Low vs. moderate

low vs. high

moderate vs. high. AJCC stage P-values:

I vs. II

I vs. III

II vs. III. CRM1, chromosome region maintenance 1; HBsAg, hepatitis B surface antigen; HBeAg, hepatitis B envelope antigen; AFP, α-fetoprotein; AJCC, American Joint Committee on Cancer; +, positive; -, negative.
